Clomiphene-responsive hypogonadism in sickle cell anemia

Area of Science:

• Endocrinology
• Hematology
• Reproductive Medicine

Background:

• Sickle cell anemia (SCA) is frequently associated with hypogonadism.
• The underlying mechanisms of hypogonadism in SCA are not fully understood.
• This study investigates hypothalamic dysfunction as a cause of hypogonadism in SCA.

Observation:

• Two 19-year-old males with SCA and hypogonadism presented with partial hypothalamic hypogonadism.
• Patients exhibited low testosterone and low to low-normal gonadotropin levels.
• Iron deficiency and severe hemolytic anemia were noted, but no nutritional deficiencies or anatomical lesions were identified.

Findings:

• Hypothalamic dysfunction was diagnosed based on hormonal profiles and response to gonadotropin-releasing hormone stimulation.
• Oral clomiphene treatment successfully elevated luteinizing hormone, follicle-stimulating hormone, and testosterone levels to normal ranges.
• Puberty was induced in both patients with clomiphene therapy.

Implications:

• Clomiphene citrate represents a viable treatment option for hypogonadism secondary to hypothalamic dysfunction in sickle cell anemia patients.
• Thorough evaluation of severe hypogonadism in SCA is crucial.
• Further research into the long-term efficacy and safety of clomiphene in this population is warranted.